Long non-coding RNA ATB promotes growth and epithelial-mesenchymal transition and
predicts poor prognosis in human prostate carcinoma
#MMPMID27176634
Xu S
; Yi XM
; Tang CP
; Ge JP
; Zhang ZY
; Zhou WQ
Oncol Rep
2016[Jul]; 36
(1
): 10-22
PMID27176634
show ga
Long non-coding RNAs (lncRNAs) have been identified to be critical mediators in
various tumors associated with cancer progression. Long non-coding RNA activated
by TGF-? (lncRNA-ATB) is a stimulator of epithelial-mesenchymal transition (EMT)
and serves as a novel prognostic biomarker for hepatocellular carcinoma. However,
the biological role and clinical significance of lncRNA-ATB in human prostate
cancer have yet to be fully elucidated. The present study was designed to explore
the expression of lncRNA-ATB in human prostate cancer patients and the role of
lncRNA-ATB in prostate cancer cells. We showed that lncRNA-ATB expression was
significantly upregulated in tumor tissues in patients with prostate cancer in
comparison with adjacent non-tumor tissues. Further analysis indicted that high
lncRNA-ATB expression may be an independent prognostic factor for biochemical
recurrence (BCR)-free survival in prostate cancer patients. Overexpression of
lncRNA-ATB promoted, and knockdown of lncRNA-ATB inhibited the growth of prostate
cancer cells via regulations of cell cycle regulatory protein expression levels.
In addition, lncRNA-ATB stimulated epithelial-mesenchymal transition (EMT)
associated with ZEB1 and ZNF217 expression levels via ERK and PI3K/AKT signaling
pathways. These results indicated that lncRNA-ATB may be considered as a new
predictor in the clinical prognosis of patients with prostate cancer.
Overexpression of lncRNA-ATB exerts mitogenic and EMT effects of prostate cancer
via activation of ERK and PI3K/AKT signaling pathways.
free
free
free
